Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans.
Article Details
- CitationCopy to clipboard
Sanchez-Ponce R, Wang LQ, Lu W, von Hehn J, Cherubini M, Rush R
Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans.
Metabolites. 2012 Sep 11;2(3):596-613. doi: 10.3390/metabo2030596.
- PubMed ID
- 24957649 [ View in PubMed]
- Abstract
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-enantiomers of baclofen presents scientific evidence for stereoselective metabolism of only S-baclofen to an abundant oxidative deamination metabolite that is sterically resolved as the S-enantiomeric configuration. This metabolite undergoes some further metabolism by glucuronide conjugation. Consequences of this metabolic difference are a lower Cmax and lower early plasma exposure of S-baclofen compared to R-baclofen and marginally lower urinary excretion of S-baclofen after racemic baclofen administration. These differences introduce compound-related exposure variances in humans in which subjects dosed with racemic baclofen are exposed to a prominent metabolite of baclofen whilst subjects dosed with STX209 are not. For potential clinical use, our findings suggest that STX209 has the advantage of being a biologically defined and active enantiomer.
DrugBank Data that Cites this Article
- Drug Reactions
Reaction Details
